

The International Federation of Clinical Chemistry – Scientific Division (IFCC-SD) and the Greek Society of Clinical Chemistry – Clinical Biochemistry Organize a Joint Hybrid Symposium.

Medical Test Performance should keep pace with Evolution in Science and Clinical Guidelines: State of play and challenges for CardioVascular Disease tests in this era of Precision Medicine.

2 OCTOBER 2022

HERAKLEION - CRETA GREECE

LOCAL TIME 11:00 - 13:00

NEW YORK TIME 04:00AM - 06:00AM

CENTRAL EUROPEAN TIME 10:00 - 12:00

SIDNEY TIME 18:00 - 20:00

MODERATORS

Prof. Christa Cobbaert (IFCC-SD)

Dr. Konstantinos Makris (IFCC-SD and GSCC-CB)



Prof. Christa M. COBBAERT

IFCC-SD VICE CHAIR

Laboratory Specialist and Head of the Department of Clinical Chemistry and Laboratory Medicine
Leiden University Medical Centre Postbus 9600 Postzone E2-P 2300 RC Leiden - The Netherlands

c.m.cobbaert@lumc.nl



Dr. Konstantinos Makris

MEMBER OF IFCC SCIENTIFIC DIVISION EXECUTIVE COMMITTEE

Clinical Biochemist

Director of Clinical Biochemistry Department KAT General Hospital
2 Nikis street, 14561, Kifissia, Athens, Greece

kostas.makris@kat-hosp.gr



Prof. Mauro Panteghini

Research Centre for Metrological Traceability in Laboratory Medicine (CIRME), University of Milan,
Milan, Italy

mauro.panteghini@unimi.it



Dr. Yannis Sdranis

Clinical Biochemist

Department of Biochemistry, University General Hospital of Ioannina
Ioannina, Greece

ysdranis@hotmail.com



Dr. Luise Luckau

Lead Researcher Protein Mass Spectrometry - Organic Analysis

National Measurement Laboratory

LGC, Queens Road, Teddington, Middlesex, TW11 0LY UK

luise.luckau@lgcgroup.com

LECTURE TITLE

LECTURER

The role of conventional biomarkers on the long-term CVD risk estimation. New approaches on the analytical performance standardization and the traceability of the measurements.

Dr. Yannis Sdranis

Current ESC/EAS clinical guideline demands accurate and fit-for-purpose apolipoprotein biomarkers beyond serum lipids.

Prof. Christa Cobbaert

Judging the clinical suitability of analytical performance of cardiac troponin assays.

Dr. Mauro Panteghini

Progress on Standardisation of brain natriuretic peptides

Dr. Luise Luckau

The objectives of the symposium could be summarized so as to give answers to the following questions:

1. What clinical performance do clinicians expect from cardiovascular disease (CVD) tests (described in clinical guidelines)?
2. What does this imply for the analytical performance requirements (among them bias, imprecision, selectivity at the low end, interference budget, MU) of these CVD tests?
3. Are the interdependent analytical and clinical performance requirements sufficiently aligned and do they guarantee that CVD tests are clinically fit-for purpose? Or do we need better tests?
4. What are the activities from relevant IFCC WG or C (each speaker participates) now and future goals?